Last reviewed · How we verify
Lipenan (CLOFIBRIDE)
Lipenan (generic name: CLOFIBRIDE) is a clofibride drug. It is currently in Phase 2 development.
Lipenan works by inhibiting the synthesis of triglycerides in the liver.
Lipenan, also known as CLOFIBRIDE, is a small molecule drug in the clofibride class. It is a lipid-lowering agent, but its exact target and approved indications are unknown. The commercial status of Lipenan is unclear, and it may be patented or generic. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLOFIBRIDE |
|---|---|
| Drug class | clofibride |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
Think of it like a brake on a car - Lipenan slows down the liver's production of triglycerides, which are a type of fat that can build up in the blood and increase the risk of heart disease. By reducing triglyceride levels, Lipenan can help lower the risk of heart problems. This is especially important for people with high levels of triglycerides in their blood.
Approved indications
Common side effects
Key clinical trials
- Weight Gain Prevention in Adolescents and Young Adults (PHASE3)
- Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity (PHASE2)
- Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity (PHASE2)
- A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents (PHASE4)
- FDA Approved Medication to Reduce Binge Eating and/or Purging (PHASE1)
- Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects (PHASE4)
- A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipenan CI brief — competitive landscape report
- Lipenan updates RSS · CI watch RSS
Frequently asked questions about Lipenan
What is Lipenan?
How does Lipenan work?
What is the generic name of Lipenan?
What drug class is Lipenan in?
What development phase is Lipenan in?
Related
- Drug class: All clofibride drugs
- Therapeutic area: All drugs in Gastroenterology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing